Lake Street lowered the firm’s price target on TriSalus Life Sciences (TLSI) to $8 from $10 and keeps a Buy rating on the shares. The firm reduced its 2026 and 2027 revenue and AEBITDA estimates, but expects a sharp return to 30% growth in the second half and thinks this, coupled with new clinical data and product approvals, will support a rebound in shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TLSI:
- TriSalus Life Sciences reports Q EPS 3c, one estimate (16c)
- TriSalus announces journal publication of PEDD study
- TriSalus Life Sciences Announces Planned Clinical Leadership Transition
- TriSalus Life Sciences appoints Marshall as Chief Medical Officer
- TriSalus Life Sciences Names Richard Marshall Chief Medical Officer